Want to see ENTA full AI Analyst Report?
ENTA Stock Chart & Stats
$13.80
-$0.05(-0.39%)
At close: 4:00 PM EDT
$13.80
-$0.05(-0.39%)
Day’s Range― - ―
52-Week Range$7.05 - $17.15
Previous Close$12.73
Volume91.84K
Average Volume (3M)203.76K
Market Cap
$408.34M
Enterprise Value$416.67
Total Cash (Recent Filing)$189.51M
Total Debt (Recent Filing)$55.66M
Price to Earnings (P/E)―
Beta1.61
Next Earnings
Nov 16, 2026EPS Estimate
-0.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.41
Shares Outstanding29,125,402
10 Day Avg. Volume264,252
30 Day Avg. Volume203,764
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)3.95
Price to Sales (P/S)3.91
P/FCF Ratio-7.94
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$20.00Price Target Upside44.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.44
Revenue Forecast (FY)$65.46M
Bulls Say, Bears Say
Bulls Say
High Gross MarginThe very high gross margin indicates that partnered products and licensing activities can generate substantial economic value after direct costs, providing a strong foundation if Enanta's pipeline produces additional commercial or royalty revenue.
Improved LeverageLower debt and positive equity improve financial flexibility compared with prior periods. This gives Enanta more capacity to fund clinical development and manage operations while reducing the balance-sheet pressure associated with earlier leverage levels.
Late-Stage RSV PipelineAdvancing zelicapavir into registrational studies creates a meaningful path toward a potentially commercial RSV product. Positive adult and pediatric data, Fast Track status, and a large unmet need could strengthen Enanta's partnering and revenue prospects.
Bears Say
Persistent Losses And Revenue DeclineDeep operating losses combined with declining revenue show that Enanta has not yet translated its scientific assets into a self-sustaining business. Continued cost burdens may limit investment capacity and increase dependence on future pipeline success.
Negative Cash GenerationPersistent cash burn means the company cannot currently fund operations and clinical programs internally. Enanta may need to draw on its balance sheet, raise equity, or secure partners, creating execution risk and potential dilution over the development cycle.
Patent Litigation SetbackThe adverse appellate decision reduces Enanta's ability to seek damages from Pfizer and weakens the immediate leverage of a key patent asset. It may also affect perceptions of future IP enforcement and the company's ability to recoup antiviral R&D costs.
Enanta Pharmaceuticals News
ENTA FAQ
What was Enanta Pharmaceuticals’s price range in the past 12 months?
Enanta Pharmaceuticals lowest stock price was $7.05 and its highest was $17.15 in the past 12 months.
What is Enanta Pharmaceuticals’s market cap?
Enanta Pharmaceuticals’s market cap is $408.34M.
When is Enanta Pharmaceuticals’s upcoming earnings report date?
Enanta Pharmaceuticals’s upcoming earnings report date is Nov 16, 2026 which is in 72 days.
How were Enanta Pharmaceuticals’s earnings last quarter?
Enanta Pharmaceuticals released its earnings results on Aug 10, 2026. The company reported -$0.67 earnings per share for the quarter, missing the consensus estimate of -$0.51 by -$0.16.
Is Enanta Pharmaceuticals overvalued?
According to Wall Street analysts Enanta Pharmaceuticals’s price is currently Undervalued.
Does Enanta Pharmaceuticals pay dividends?
Enanta Pharmaceuticals does not currently pay dividends.
What is Enanta Pharmaceuticals’s EPS estimate?
Enanta Pharmaceuticals’s EPS estimate is -0.77.
How many shares outstanding does Enanta Pharmaceuticals have?
Enanta Pharmaceuticals has 29,125,402 shares outstanding.
What happened to Enanta Pharmaceuticals’s price movement after its last earnings report?
Enanta Pharmaceuticals reported an EPS of -$0.67 in its last earnings report, missing expectations of -$0.51. Following the earnings report the stock price went down -2.1%.
Which hedge fund is a major shareholder of Enanta Pharmaceuticals?
Currently, no hedge funds are holding shares in ENTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Enanta Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.00 (44.93% Upside)
$20.00 (44.93% Upside)
Blogger Sentiment
Neutral
ENTA Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 453.7K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
58.38%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.38%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
ENTA Stock 12 Month Forecast
Average Price Target
$20.00
▲(44.93% Upside)
Technical Analysis
Abeona Therapeutics
―
Tectonic Therapeutic
―
Allogene Therapeutics
―
Jade Biosciences
―
Neumora Therapeutics, Inc.
―
Ownership Overview
4.74% Insiders
13.30% Mutual Funds
35.35% Other Institutional Investors
35.25% Public Companies and
Individual Investors